Kainos Laboratories, Inc. (JP:4556)
:4556
Want to see JP:4556 full AI Analyst Report?
4556 Stock Chart & Stats
¥1271.00
¥2.00(0.16%)
At close: 4:00 PM EST
¥1271.00
¥2.00(0.16%)
Day’s Range― - ―
52-Week Range¥1,129.00 - ¥2,284.00
Previous CloseN/A
Volume2.10K
Average Volume (3M)3.67K
Market Cap
¥9.28B
Enterprise Value¥2.52B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)9.5
Beta0.55
Next Earnings
May 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.53%
Share Statistics
EPS (TTM)105.98
Shares Outstanding4,558,860
10 Day Avg. Volume3,280
30 Day Avg. Volume3,666
Financial Highlights & Ratios
PEG Ratio-62.73
Price to Book (P/B)0.78
Price to Sales (P/S)1.00
P/FCF Ratio8.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Free Cash Flow GenerationKainos converts earnings into cash very effectively: FCF growth of 78.44% and FCF/NI ~0.99 indicate durable operating cash conversion. This underpins sustainable funding for R&D, dividends, capex or buybacks and reduces reliance on external financing over the medium term.
Conservative Balance Sheet / Low LeverageVery low debt-to-equity and a high equity ratio provide structural financial resilience. This conservative capital structure lowers refinancing risk, gives flexibility for strategic investments or M&A, and supports stability through industry cycles over the coming months.
High Margins And Operational EfficiencyRobust gross and EBITDA margins reflect product mix and operational discipline in diagnostics reagents. Sustained margin levels imply pricing power or manufacturing efficiency, enabling internal reinvestment in product development and protecting profitability against cost fluctuations.
Bears Say
Modest Revenue GrowthTop-line expansion is limited, with sub-5% reported growth year-over-year. For a specialized diagnostics firm, modest revenue acceleration may constrain economies of scale and limit the pace at which margins or absolute profits can expand absent new product launches or geographic expansion.
Moderate Return On EquityROE under 10% suggests only moderate effectiveness converting equity into profits despite low leverage. With a high equity base, management must improve asset or capital efficiency to boost long-term shareholder returns or demonstrate higher incremental returns on new investments.
Small Scale / Concentration RiskA small, specialized organization with concentrated product focus raises execution and customer-concentration risks. Limited scale can slow market penetration, make R&D and regulatory cost absorption harder, and increase sensitivity to demand swings in core clinical segments.
4556 FAQ
What was Kainos Laboratories, Inc.’s price range in the past 12 months?
Kainos Laboratories, Inc. lowest stock price was ¥1129.00 and its highest was ¥2284.00 in the past 12 months.
What is Kainos Laboratories, Inc.’s market cap?
Kainos Laboratories, Inc.’s market cap is ¥9.28B.
When is Kainos Laboratories, Inc.’s upcoming earnings report date?
Kainos Laboratories, Inc.’s upcoming earnings report date is May 08, 2026 which is in 16 days.
How were Kainos Laboratories, Inc.’s earnings last quarter?
Kainos Laboratories, Inc. released its earnings results on Jan 27, 2026. The company reported ¥105.98 earnings per share for the quarter, beating the consensus estimate of N/A by ¥105.98.
Is Kainos Laboratories, Inc. overvalued?
According to Wall Street analysts Kainos Laboratories, Inc.’s price is currently Overvalued.
Does Kainos Laboratories, Inc. pay dividends?
Kainos Laboratories, Inc. pays a Annually dividend of ¥32 which represents an annual dividend yield of 2.53%. See more information on Kainos Laboratories, Inc. dividends here
What is Kainos Laboratories, Inc.’s EPS estimate?
Kainos Laboratories, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kainos Laboratories, Inc. have?
Kainos Laboratories, Inc. has 4,558,860 shares outstanding.
What happened to Kainos Laboratories, Inc.’s price movement after its last earnings report?
Kainos Laboratories, Inc. reported an EPS of ¥105.98 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -4.357%.
Which hedge fund is a major shareholder of Kainos Laboratories, Inc.?
Currently, no hedge funds are holding shares in JP:4556
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kainos Laboratories, Inc.
KAINOS Laboratories, Inc. engages in the development, manufacture, marketing, distribution, and import/export of pharmaceuticals, diagnostic reagents, and related chemical products in Japan. It is also involved in the development, manufacture, marketing, distribution, and import/export of physical and chemical measurement instruments, and medical supplies, as well as nutrition supplements, foodstuff, animal feed, and related products. The company offers various biochemical clinical testing reagents systems, such as Aqua-auto Kainos CRE-IV Test Kit, a liquid form creatinine measurement reagent kit for various makes of automatic analyzer systems; Aqua-auto Kainos ALB Test Kit, a liquid form reagent kit; and Aqua-auto Kainos UN-II Test Kit, a liquid urea nitrogen measurement reagent kit. In addition, it provides FGF-23 ELISA Kit, a two-site enzyme-linked immunosorbent assay kit for the measurement of FGF-23 in serum. Further, the company offers point of care testing solutions comprising Swiftgene Norovirus GI/GII Kainos for detecting noroviruses; Statmark FLUstick II for detecting type A and type B influenza virus antigens; and Statmark Strep A for detecting Group A beta-hemolytic streptococci. The company was formerly known as DOMS-IATRON Co., Ltd. and changed its name to KAINOS Laboratories, Inc. in July 1975. KAINOS Laboratories, Inc. was founded in 1975 and is headquartered in Tokyo, Japan.